Oestrogen receptors α and β show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer
Oestrogen receptors α and β show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer
复制标题
DOI：
10.1136/jcp.2006.040378
复制
发表时间：
2008-02-01
影响因子：
3.4
通讯作者：
Jirstrom, K.
中科院分区：
文献类型：
--
作者：
Borgquist, S.;Holm, C.;Jirstrom, K.
目的：大多数乳腺癌是激素敏感的，传统上由雌激素受体(ER)α和/或孕激素受体的表达来定义。与ERα相比，最近发现的ERβ的临床意义仍不清楚。本研究旨在明确ERβ与乳腺癌临床病理参数的关系，并进一步探讨ERβ表达对疾病转归的影响。方法：应用免疫组织化学方法，分析1988-1992年马尔莫大学医院确诊的512例乳腺癌患者ERα和ERβ的免疫组织化学表达。结果：78%的肿瘤ERα阳性，50%ERβ阳性。ERβ与ERα呈正相关(p=0.001)。与ERα相反，ERβ与任何重要的临床病理变量无关。此外，ERβ也不具有整体预后意义。然而，在ERα阳性的亚组中，ERβ的低表达与接受内分泌治疗的患者的无病生存率下降相关(p=0.003)。结论：尽管ERα和ERβ相互关联，但它们似乎与临床病理参数存在差异，这支持了它们在体内可能具有不同功能的事实。此外，ERβ可能是内分泌治疗反应的预测标记物，尽管这需要在其他研究中得到证实，最好是随机试验。
Aims: The majority of all breast cancers are hormone responsive, traditionally defined by the expression of oestrogen receptor (ER) alpha and/or progesterone receptors. In contrast to ER alpha, the clinical significance of the relatively recently identified ER beta is still unclear. This study aimed to define the relationship between ER beta and clinicopathological parameters in a mixed cohort of breast cancer and, furthermore, to investigate the impact of ER beta expression on disease outcome.Methods: The immunohistochemical expression of ER alpha and ER beta was analysed in tissue microarrays containing a total number of 512 tumours with all incident breast cancers diagnosed at the Malmo University Hospital between 1988 and 1992.Results: 78% of the tumours were ER alpha positive and 50% were ER beta positive. ER beta correlated positively with ER alpha (p = 0.001). In contrast to ER alpha, ER beta was not associated with any important clinicopathological variables.Furthermore, no overall prognostic significance could be demonstrated for ER beta. In the ER alpha-positive subgroup, however, a low expression of ER beta correlated with a decreased disease-free survival in patients receiving endocrine treatment (p = 0.003).Conclusions: Although interrelated, ER alpha and ER beta seem to be differentially associated to clinicopathological parameters, and this would support the fact that they might have different functions in vivo. Furthermore, ER beta might be a predictive marker of response to endocrine therapy, although this needs to be confirmed in additional studies, preferably randomised trials.